Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

DPUK’s investment in this work, establishing an active network of researchers from academia and industry focusing on synaptic health, has been one of its success stories. The network successfully secured funding for a Phase 0 experimental medicine study (New Targets in Alzheimer’s Disease; ‘NTAD’) which is currently on-going and has started to generate important outputs. The network also identified tractable experimental medicine questions, secured new grant funding and contributed to on-going MRC studies (MINDMAPS and Deep and Frequent Phenotyping) as well as international initiatives (JPND) on data harmonisation and standardisation for MEG in dementia research. The network remains very active holding workshops and regular teleconferences to further progress these challenging studies; a new proposed study formed part of the experimental medicine theme for which funding has been sought for DPUK2.


DPUK final report